Larkspur Biosciences kicks off with $30M+, hunting for new oncology immunotherapies

Paul Schloesser

Associate Editor

Based in Massachusetts, Larkspur Biosciences, a biotech focused on developing new immuno-oncology treatments, is now armed with $35.5 million in combined …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Larkspur Biosciences kicks off with $30M+, hunting for new oncology immunotherapies

Paul Schloesser

Associate Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Larkspur Biosciences kicks off with $30M+, hunting for new oncology immunotherapies